Biosphere’s proprietary UV sterilization approach paves the way for a new generation of bioreactors that are simpler, more ...

Cannabix provides updated images of its Breath Collection Unit (“BCU”) and Breath Cartridge technology with several new ...

Passer à la cigarette électronique pour s’arrêter de fumer, puis décider de s’arrêter de vapoter, c’est l’itinéraire choisi ...

Frontier’s pipeline of precision medicines continues to progress rapidly, with interim clinical data for FMC-376, an ON+OFF KRASG12C inhibitor currently in the Phase 1/2 PROSPER trial, expected 2H ...

Immuno-oncological therapies have transformed the cancer treatment landscape. They are however only effective in a subset of patients, requiring the identification of novel immunotherapy targets. The ...

Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciences Meet BioLizard’s Arjan van Manen and CEO Liesbeth Ceelen at Biotech ...

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

ElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company commercializes its enabling technologies, manufacturing ...

MISSOULA, Mont., Jan. 09, 2025 (GLOBE NEWSWIRE) -- FYR, a visionary biotechnology company leveraging extracellular vesicles (EVs) to dynamically observe disease and treatment responses, today ...

BOSTON, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a global leader in digital care, today announced it has sold its Amwell Psychiatric Care (APC) business to Avel eCare, a national ...

J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of innovation and growing visibility around women’s health.

In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...